The American Journal of Medicine
Volume 120, Issue 1 , Pages 5-11 , January 2007

From Here to Eternity: A Unified Kinetic Model for the Pathophysiology of Atherosclerotic Events

  • George A. Diamond, MD

      Affiliations

    • Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, Calif
    • David Geffen School of Medicine, University of California, Los Angeles.
    • Corresponding Author InformationRequests for reprints should be addressed to George A. Diamond, MD, 2408 Wild Oak Drive, Los Angeles, CA 90068.
    • ,
  • Sanjay Kaul, MD

      Affiliations

    • Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, Calif
    • David Geffen School of Medicine, University of California, Los Angeles.

References 

  1. Gorlin R. Treatment of chronic stable angina pectoris. Am J Cardiol. 1992;70:26G–31G
  2. Sheridan PJ, Crossman DC. Critical review of unstable angina and non-ST elevation myocardial infarction. Postgrad Med. 2002;78:717–726
  3. Acampa W, Petretta M, Cuocolo A. Nuclear medicine procedures in cardiovascular diseases (An evidence based approach). Q J Nucl Med. 2002;46:323–330
  4. Rogers WJ, Bourassa MG, Andrews TC, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization (The ACIP investigators). J Am Coll Cardiol. 1995;26:594–605
  5. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2–II10
  6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  7. Ridker PM, Manson JE, Buring JE, Goldhaber SZ, Hennekens CH. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians’ Health Study. Am Heart J. 1991;122:1588–1592
  8. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  9. Mehra J. The Physicist’s Conception of Nature. Dordrecht, Holland: Reidel; 1973;
  10. Ladenheim ML, Kotler TS, Pollock BH, Berman DS, Diamond GA. Incremental prognostic power of clinical history, exercise electrocardiography and myocardial perfusion scintigraphy in suspected coronary artery disease. Am J Cardiol. 1987;59:270–277
  11. Diamond GA. Future imperfect: the limitations of clinical prediction models and the limits of clinical prediction. J Am Coll Cardiol. 1989;14:12A–22A
  12. Alberty RA, Miller WG. Integrated rate equations for isotopic exchange in simple reversible reactions. J Chem Phys. 1957;26:1231–1237
  13. Diamond GA, Kaul S. Hazardous to your health: kinetic foundations of risk stratification and therapeutic triage. Am J Med. 2006;119:275;e1-6
  14. Itchhaporia D, Snow PB, Almassy RJ, Oetgen WJ. Artificial neural networks: current status in cardiovascular medicine. J Am Coll Cardiol. 1996;28:515–521
  15. Braunwald E. Unstable angina: an etiologic approach to management. Circulation. 1998;98:2219–2222
  16. Stefan K, Johann W. The natural course of atherosclerosis (Part I: Incidence and progression). Arterioscler Thromb Vas Biol. 1999;19:1484–1490
  17. Libby P. The vascular biology of atherosclerosis. In:  Braunwald E,  Zipes DP,  Libby P editor. Heart Disease: A Textbook of Cardiovascular Medicine. 6th ed.. Philadelphia, Pennsylvania: Saunders; 2001;p. 995–1009
  18. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl II):38–46
  19. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671
  20. Litchfield RL. Noninvasive tests for cardiac risk stratification (Which ones are most prognostic?). Postgrad Med. 2004;115:30–36
  21. Kamineni R, Alpert JS. Acute coronary syndromes: initial evaluation and risk stratification. Prog Cardiovasc Dis. 2004;46:379–392
  22. Eagle KA, Lim MJ, Dabbous OH, et al. GRACE investigators (A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry). JAMA. 2004;291:2727–2733
  23. Veillard NR, Steffens S, Burger F, Pelli G, Mach F. Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler Thromb Vasc Biol. 2004;24:2339–2344
  24. Laham RJ, Carrozza JP, Berger C, Choen DJ, Kuntz RE, Baim DS. Long-term (4- to 6-year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. J Am Coll Cardiol. 1996;28:820–826
  25. Cederholm A, Svenungsson E, Jensen-Urstad K, et al. Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol. 2005;25:198–203
  26. Cohn JN. Evaluating pathophysiologic processes rather than clinical end points in improving therapeutic practice. Cardiovasc Pharmacol. 1998;32(Suppl 3):S38–S40
  27. Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol. 2003;41:1293–1304
  28. Johnson BD, Shaw LJ, Buchthal SD, et al. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease (Results from the National Institutes of Health—National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE)). Circulation. 2004;109:2993–2999
  29. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664–1672
  30. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772–1778
  31. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherosclerosis. J Am Coll Cardiol. 2004;44:2293–2300
  32. Daniels F, Alberty RA. In: Physical Chemistry. New York, New York: John Wiley; 1961;p. 295–313
  33. Redberg RF, Rifai N, Gee L, Ridker PM. Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol. 2000;36:39–43
  34. Park R, Detrano R, Xiang M, et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation. 2002;106:2073–2077

PII: S0002-9343(06)00567-5

doi: 10.1016/j.amjmed.2006.04.021

The American Journal of Medicine
Volume 120, Issue 1 , Pages 5-11 , January 2007

Article Tools

* Image Usage & Resolution